<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39626064</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.</ArticleTitle><Pagination><StartPage>1730</StartPage><EndPage>1753</EndPage><MedlinePgn>1730-1753</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14309/ajg.0000000000002968</ELocationID><Abstract><AbstractText>Helicobacter pylori is a prevalent, global infectious disease that causes dyspepsia, peptic ulcer disease, and gastric cancer. The American College of Gastroenterology commissioned this clinical practice guideline (CPG) to inform the evidence-based management of patients with H. pylori infection in North America. This CPG used Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology to systematically analyze 11 Population, Intervention, Comparison, and Outcome questions and generate recommendations. Where evidence was insufficient or the topic did not lend itself to GRADE, expert consensus was used to create 6 key concepts. For treatment-naive patients with H. pylori infection, bismuth quadruple therapy (BQT) for 14 days is the preferred regimen when antibiotic susceptibility is unknown. Rifabutin triple therapy or potassium-competitive acid blocker dual therapy for 14 days is a suitable empiric alternative in patients without penicillin allergy. In treatment-experienced patients with persistent H. pylori infection, "optimized" BQT for 14 days is preferred for those who have not been treated with optimized BQT previously and for whom antibiotic susceptibility is unknown. In patients previously treated with optimized BQT, rifabutin triple therapy for 14 days is a suitable empiric alternative. Salvage regimens containing clarithromycin or levofloxacin should only be used if antibiotic susceptibility is confirmed. The CPG also addresses who to test, the need for universal post-treatment test-of-cure, and the current evidence regarding antibiotic susceptibility testing and its role in guiding the choice of initial and salvage treatment. The CPG concludes with a discussion of proposed research priorities to address knowledge gaps and inform future management recommendations in patients with H. pylori infection from North America.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by The American College of Gastroenterology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chey</LastName><ForeName>William D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howden</LastName><ForeName>Colin W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>University of Tennessee College of Medicine, Memphis, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Steven F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Providence VA Medical Center, Rhode Island Hospital &amp; Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greer</LastName><ForeName>Katarina B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Louis Stokes Cleveland Veteran Affairs Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grover</LastName><ForeName>Shilpa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Shailja C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, VA San Diego Healthcare System, Division of Gastroenterology, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>American College of Gastroenterology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>U015TT5I8H</RegistryNumber><NameOfSubstance UI="D001729">Bismuth</NameOfSubstance></Chemical><Chemical><RegistryNumber>H1250JIK0A</RegistryNumber><NameOfSubstance UI="D017291">Clarithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>1W306TDA6S</RegistryNumber><NameOfSubstance UI="D017828">Rifabutin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001729" MajorTopicYN="Y">Bismuth</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017291" MajorTopicYN="N">Clarithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016481" MajorTopicYN="Y">Helicobacter Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016480" MajorTopicYN="Y">Helicobacter pylori</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017828" MajorTopicYN="N">Rifabutin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39626064</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000002968</ArticleId><ArticleId IdType="pii">00000434-202409000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017;153(2):420&#x2013;9.</Citation></Reference><Reference><Citation>de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health 2020;8(2):e180&#x2013;90.</Citation></Reference><Reference><Citation>Pennelli G, Grillo F, Galuppini F, et al. Gastritis: Update on etiological features and histological practical approach. Pathologica 2020;112(3):153&#x2013;65.</Citation></Reference><Reference><Citation>Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. Nat Rev Dis Primers 2023;9(1):19.</Citation></Reference><Reference><Citation>Makristathis A, Hirschl AM, Megraud F, et al. Review: Diagnosis of Helicobacter pylori infection. Helicobacter 2019;24(Suppl 1):e12641.</Citation></Reference><Reference><Citation>Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112(2):212&#x2013;39.</Citation></Reference><Reference><Citation>Li Y, Choi H, Leung K, et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023;8(6):553&#x2013;64.</Citation></Reference><Reference><Citation>Megraud F, Lehours P, Vale FF. The history of Helicobacter pylori: From phylogeography to paleomicrobiology. Clin Microbiol Infect 2016;22(11):922&#x2013;7.</Citation></Reference><Reference><Citation>Thorell K, Munoz-Ramirez ZY, Wang D, et al. The Helicobacter pylori Genome Project: Insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Nat Commun 2023;14(1):8184.</Citation></Reference><Reference><Citation>Taylor DN, Sanchez JL, Smoak BL, et al. Helicobacter pylori infection in Desert Storm troops. Clin Infect Dis 1997;25(5):979&#x2013;82.</Citation></Reference><Reference><Citation>Hyams KC, Taylor DN, Gray GC, et al. The risk of Helicobacter pylori infection among U.S. military personnel deployed outside the United States. Am J Trop Med Hyg 1995;52(1):109&#x2013;12.</Citation></Reference><Reference><Citation>Duan M, Li Y, Liu J, et al. Transmission routes and patterns of Helicobacter pylori. Helicobacter 2023;28(1):e12945.</Citation></Reference><Reference><Citation>Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102(8):1808&#x2013;25.</Citation></Reference><Reference><Citation>Gravina AG, Zagari RM, De Musis C, et al. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol 2018;24(29):3204&#x2013;21.</Citation></Reference><Reference><Citation>Franceschi F, Covino M, Roubaud Baudron C. Review: Helicobacter pylori and extragastric diseases. Helicobacter 2019;24(Suppl 1):e12636.</Citation></Reference><Reference><Citation>de Martel C, Parsonnet J. Helicobacter pylori infection and gender: A meta-analysis of population-based prevalence surveys. Dig Dis Sci 2006;51(12):2292&#x2013;301.</Citation></Reference><Reference><Citation>Ibrahim A, Morais S, Ferro A, et al. Sex-differences in the prevalence of Helicobacter pylori infection in pediatric and adult populations: Systematic review and meta-analysis of 244 studies. Dig Liver Dis 2017;49(7):742&#x2013;9.</Citation></Reference><Reference><Citation>Jalaly JB, Couturier MR, Burnham CD, et al. Multicenter evaluation of Helicobacter pylori IgG antibody seroprevalence among patients seeking clinical care in the US. J Appl Lab Med 2018;2(6):904&#x2013;13.</Citation></Reference><Reference><Citation>Shah SC, Halvorson AE, Lee D, et al. Helicobacter pylori burden in the United States according to individual demographics and geography: A nationwide analysis of the Veterans Healthcare System. Clin Gastroenterol Hepatol 2024;22(1):42&#x2013;50.e26.</Citation></Reference><Reference><Citation>Morais S, Costa AR, Ferro A, et al. Contemporary migration patterns in the prevalence of Helicobacter pylori infection: A systematic review. Helicobacter 2017;22(3):12372.</Citation></Reference><Reference><Citation>Delaney B, Ford AC, Forman D, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2005(4):CD001961.</Citation></Reference><Reference><Citation>Anderson WF, Rabkin CS, Turner N, et al. The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. J Natl Cancer Inst 2018;110(6):608&#x2013;15.</Citation></Reference><Reference><Citation>Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: Management of dyspepsia. Am J Gastroenterol 2017;112(7):988&#x2013;1013.</Citation></Reference><Reference><Citation>Committee ASoP, Shaukat A, Wang A, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc 2015;82(2):227&#x2013;32.</Citation></Reference><Reference><Citation>Wechsler EV, Ahuja NK, Brenner D, et al. Up-front endoscopy maximizes cost-effectiveness and cost-satisfaction in uninvestigated dyspepsia. Clin Gastroenterol Hepatol 2023;21(9):2378&#x2013;88.e28.</Citation></Reference><Reference><Citation>Ford AC, Tsipotis E, Yuan Y, et al. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: Updated systematic review and meta-analysis. Gut 2022;71(10):1967&#x2013;75.</Citation></Reference><Reference><Citation>Koletzko L, Macke L, Schulz C, et al. Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit. Best Pract Res Clin Gastroenterol 2019;40&#x2013;41:101637.</Citation></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7&#x2013;30.</Citation></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209&#x2013;49.</Citation></Reference><Reference><Citation>Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391(10125):1023&#x2013;75.</Citation></Reference><Reference><Citation>Rustgi SD, McKinley M, McBay B, et al. Epidemiology of gastric malignancies 2000-2018 according to histology: A population-based analysis of incidence and temporal trends. Clin Gastroenterol Hepatol 2023;21(13):3285&#x2013;95.e8.</Citation></Reference><Reference><Citation>Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020;18(3):534&#x2013;42.</Citation></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7&#x2013;33.</Citation></Reference><Reference><Citation>Shah SC, McKinley M, Gupta S, et al. Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older. Gastroenterology 2020;159(5):1705&#x2013;14.e2.</Citation></Reference><Reference><Citation>Pabla BS, Shah SC, Corral JE, et al. Increased incidence and mortality of gastric cancer in immigrant populations from high to low regions of incidence: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020;18(2):347&#x2013;59.e5.</Citation></Reference><Reference><Citation>Wang CP, McKinley M, Gomez SL, et al. Socioeconomic status and ethnic enclave as risk factors for gastric adenocarcinoma in Hispanic and Asian Americans, a California Cancer Registry analysis. Clin Gastroenterol Hepatol 2023;21(11):2968&#x2013;71.e3.</Citation></Reference><Reference><Citation>Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015;136(2):487&#x2013;90.</Citation></Reference><Reference><Citation>Gawron AJ, Shah SC, Altayar O, et al. AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes. Gastroenterology 2020;158(3):705&#x2013;31.e5.</Citation></Reference><Reference><Citation>Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: Systematic review and meta-analysis. Gut 2020;69(12):2113&#x2013;21.</Citation></Reference><Reference><Citation>Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology 2016;150(5):1113&#x2013;24.e5.</Citation></Reference><Reference><Citation>Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: A long-term cohort study on Matsu Islands. Gut 2021;70(2):243&#x2013;50.</Citation></Reference><Reference><Citation>Jung DH, Kim JH, Chung HS, et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: A meta-analysis. PLoS One 2015;10(4):e0124725.</Citation></Reference><Reference><Citation>Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: A large cohort study. Gastroenterology 2020;158(3):527&#x2013;36.e7.</Citation></Reference><Reference><Citation>Li D, Jiang SF, Lei NY, et al. Effect of Helicobacter pylori eradication therapy on the incidence of noncardia gastric adenocarcinoma in a large diverse population in the United States. Gastroenterology 2023;165(2):391&#x2013;401.e2.</Citation></Reference><Reference><Citation>Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: Genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015;16(2):e60&#x2013;70.</Citation></Reference><Reference><Citation>Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer 2010;102(2):237&#x2013;42.</Citation></Reference><Reference><Citation>Usui Y, Taniyama Y, Endo M, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med 2023;388(13):1181&#x2013;90.</Citation></Reference><Reference><Citation>Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med 2020;382(5):427&#x2013;36.</Citation></Reference><Reference><Citation>Zullo A, Hassan C, Ridola L, et al. Gastric MALT lymphoma: Old and new insights. Ann Gastroenterol 2014;27(1):27&#x2013;33.</Citation></Reference><Reference><Citation>Lemos FFB, de Castro CT, Calmon MS, et al. Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis. World J Gastroenterol 2023;29(14):2202&#x2013;21.</Citation></Reference><Reference><Citation>Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(1):17&#x2013;29.</Citation></Reference><Reference><Citation>Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut 2022;71(9):1724&#x2013;62.</Citation></Reference><Reference><Citation>Abraham SC, Montgomery EA, Singh VK, et al. Gastric adenomas: Intestinal-type and gastric-type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology. Am J Surg Pathol 2002;26(10):1276&#x2013;85.</Citation></Reference><Reference><Citation>Abraham SC, Singh VK, Yardley JH, et al. Hyperplastic polyps of the stomach: Associations with histologic patterns of gastritis and gastric atrophy. Am J Surg Pathol 2001;25(4):500&#x2013;7.</Citation></Reference><Reference><Citation>Rugge M, Bricca L, Guzzinati S, et al. Autoimmune gastritis: Long-term natural history in naive Helicobacter pylori-negative patients. Gut 2023;72(1):30&#x2013;8.</Citation></Reference><Reference><Citation>Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis: Expert review. Gastroenterology 2021;161(4):1325&#x2013;32.e7.</Citation></Reference><Reference><Citation>Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci 2019;64(10):2893&#x2013;8.</Citation></Reference><Reference><Citation>Megraud F, Graham DY, Howden CW, et al. Rates of antimicrobial resistance in Helicobacter pylori isolates from clinical trial patients across the US and Europe. Am J Gastroenterol 2023;118(2):269&#x2013;75.</Citation></Reference><Reference><Citation>Ho JJC, Navarro M, Sawyer K, et al. Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: A systematic review and meta-analysis. Am J Gastroenterol 2022;117(8):1221&#x2013;30.</Citation></Reference><Reference><Citation>Shah S, Cappell K, Sedgley R, et al. Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016&#x2013;2019. Sci Rep 2023;13(1):1375.</Citation></Reference><Reference><Citation>Liou JM, Fang YJ, Chen CC, et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet 2016;388(10058):2355&#x2013;65.</Citation></Reference><Reference><Citation>Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377(9769):905&#x2013;13.</Citation></Reference><Reference><Citation>Katelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002;123(6):1763&#x2013;9.</Citation></Reference><Reference><Citation>Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: A 24-month follow-up study. Eur J Gastroenterol Hepatol 2002;14(11):1237&#x2013;43.</Citation></Reference><Reference><Citation>Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98(3):562&#x2013;7.</Citation></Reference><Reference><Citation>Zheng Q, Chen WJ, Lu H, et al. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J Dig Dis 2010;11(5):313&#x2013;8.</Citation></Reference><Reference><Citation>Heo J, Jeon SW, Jung JT, et al. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. Dig Liver Dis 2014;46(11):980&#x2013;4.</Citation></Reference><Reference><Citation>Varga M, Dracz L, Kolbenheyer E, et al. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of Helicobacter pylori]. Orv Hetil 2019;160(34):1340&#x2013;5.</Citation></Reference><Reference><Citation>Long X, Chen Q, Yu L, et al. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018;23(3):e12485.</Citation></Reference><Reference><Citation>Calvet X, Ducons J, Guardiola J, et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection: A randomized trial. Aliment Pharmacol Ther 2002;16:1261&#x2013;7.</Citation></Reference><Reference><Citation>Jang HJ, Choi MH, Kim YS, et al. [Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication]. Korean J Gastroenterol 2005;46(5):368&#x2013;72.</Citation></Reference><Reference><Citation>Rokkas T, Gisbert JP, Malfertheiner P, et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: A network meta-analysis. Gastroenterology 2021;161(2):495&#x2013;507.e4.</Citation></Reference><Reference><Citation>Yang EH, Chen WY, Chiang HC, et al. 10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: A randomised, open-label, non-inferiority trial. EClinicalMedicine 2024;70:102529.</Citation></Reference><Reference><Citation>Nyssen OP, Perez-Aisa A, Tepes B, et al. Adverse event profile during the treatment of Helicobacter pylori: A real-world experience of 22,000 patients from the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol 2021;116(6):1220&#x2013;9.</Citation></Reference><Reference><Citation>Gingold-Belfer R, Niv Y, Levi Z, et al. Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36(6):1392&#x2013;402.</Citation></Reference><Reference><Citation>Howden CW, Shah S, Pendse SN, et al. Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2023;58(2):159&#x2013;67.</Citation></Reference><Reference><Citation>Graham DY, Canaan Y, Maher J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: A double-blind, randomized, controlled trial. Ann Intern Med 2020;172(12):795&#x2013;802.</Citation></Reference><Reference><Citation>Kalfus IN, Graham DY, Riff DS, et al. Rifabutin-containing triple therapy (RHB-105) for eradication of Helicobacter pylori: Randomized ERADICATE Hp trial. Antibiotics (Basel) 2020;9(10):685.</Citation></Reference><Reference><Citation>Abdel-Aziz Y, Metz DC, Howden CW. Review article: Potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther 2021;53(7):794&#x2013;809.</Citation></Reference><Reference><Citation>Laine L, Sharma P, Mulford DJ, et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol 2022;117(7):1158&#x2013;61.</Citation></Reference><Reference><Citation>Chey WD, Megraud F, Laine L, et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial. Gastroenterology 2022;163(3):608&#x2013;19.</Citation></Reference><Reference><Citation>Qian HS, Li WJ, Dang YN, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol 2023;118(4):627&#x2013;34.</Citation></Reference><Reference><Citation>Yan TL, Wang JH, He XJ, et al. Ten-day vonoprazan-amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A multicenter randomized clinical trial. Am J Gastroenterol 2024;119(4):655&#x2013;61.</Citation></Reference><Reference><Citation>Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther 2021;109(6):1417&#x2013;23.</Citation></Reference><Reference><Citation>Shah SC, Tepler A, Chung CP, et al. Host genetic determinants associated with Helicobacter pylori eradication treatment failure: A systematic review and meta-analysis. Gastroenterology 2021;161(5):1443&#x2013;59.</Citation></Reference><Reference><Citation>Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018;155(5):1372&#x2013;82.e17.</Citation></Reference><Reference><Citation>Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: Effect of resistance, duration, and CYP2C19 genotype. Helicobacter 2016;21(2):85&#x2013;90.</Citation></Reference><Reference><Citation>Zanichelli V, Sharland M, Cappello B, et al. The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance. Bull World Health Organ 2023;101(4):290&#x2013;6.</Citation></Reference><Reference><Citation>FDA. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 2016. (https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics). Accessed January 3, 2024.</Citation></Reference><Reference><Citation>Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study. Gut 2016;65(9):1439&#x2013;46.</Citation></Reference><Reference><Citation>Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: A randomized controlled trial. Can J Gastroenterol Hepatol 2017;2017:4385161.</Citation></Reference><Reference><Citation>Sue S, Ogushi M, Arima I, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter 2018;23(2):e12456.</Citation></Reference><Reference><Citation>Zhang M, Pang M, Zhang M. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: A meta-analysis of randomized clinical trials. Clinics (Sao Paulo) 2022;77:100058.</Citation></Reference><Reference><Citation>Malfertheiner P, Moss SF, Daniele P, et al. Potassium-competitive acid blocker and proton pump inhibitor&#x2013;based regimens for first-line Helicobacter pylori eradication: A network meta-analysis. Gastro Hep Adv 2022;1(5):824&#x2013;34.</Citation></Reference><Reference><Citation>Zagari RM, Dajti E, Cominardi A, et al. Standard bismuth quadruple therapy versus concomitant therapy for the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis of randomized controlled trials. J Clin Med 2023;12(9):3258.</Citation></Reference><Reference><Citation>Kefeli A, Basyigit S, Yeniova AO, et al. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. Bosn J Basic Med Sci 2016;16(1):52&#x2013;7.</Citation></Reference><Reference><Citation>Kim SJ, Chung JW, Woo HS, et al. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019;25(46):6790&#x2013;8.</Citation></Reference><Reference><Citation>Sezikli M, Sirin G, &#xc7;etinkaya ZA, et al. Comparison of the efficacy of six different Helicobacter pylori eradication regimens: Greater than or equal to another. Biomed Res 2018;29(6):1143&#x2013;8.</Citation></Reference><Reference><Citation>Kodama M, Murakami K, Okimoto T, et al. Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test. World J Gastroenterol 2012;18(1):44&#x2013;8.</Citation></Reference><Reference><Citation>Laine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129(7):547&#x2013;50.</Citation></Reference><Reference><Citation>Takimoto M, Tomita T, Yamasaki T, et al. Effect of vonoprazan, a potassium-competitive acid blocker, on the (13)C-urea breath test in Helicobacter pylori-positive patients. Dig Dis Sci 2017;62(3):739&#x2013;45.</Citation></Reference><Reference><Citation>Tanaka S, Goto A, Yamagishi K, et al. Long-term response of Helicobacter pylori antibody titer after eradication treatment in middle-aged Japanese: JPHC-NEXT study. J Epidemiol 2023;33:1&#x2013;7.</Citation></Reference><Reference><Citation>Batts KP, Ketover S, Kakar S, et al. Appropriate use of special stains for identifying Helicobacter pylori: Recommendations from the Rodger C. Haggitt Gastrointestinal Pathology Society. Am J Surg Pathol 2013;37(11):e12&#x2013;22.</Citation></Reference><Reference><Citation>Atkinson NS, Braden B. Helicobacter pylori infection: Diagnostic strategies in primary diagnosis and after therapy. Dig Dis Sci 2016;61(1):19&#x2013;24.</Citation></Reference><Reference><Citation>Hu Y, Wan JH, Li XY, et al. Systematic review with meta-analysis: The global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther 2017;46(9):773&#x2013;9.</Citation></Reference><Reference><Citation>Kumar S, Metz DC, Kaplan DE, et al. Low rates of retesting for eradication of Helicobacter pylori infection after treatment in the Veterans Health Administration. Clin Gastroenterol Hepatol 2021;19(2):305&#x2013;13.e1.</Citation></Reference><Reference><Citation>Chang YL, Tung YC, Tu YK, et al. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: A systemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7(1):e000472.</Citation></Reference><Reference><Citation>Yeo YH, Hsu CC, Lee CC, et al. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34(1):59&#x2013;67.</Citation></Reference><Reference><Citation>Magaret N, Burm M, Faigel D, et al. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001;19(2):174&#x2013;8.</Citation></Reference><Reference><Citation>De Francesco V, Zullo A, Manta R, et al. Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review. Eur J Gastroenterol Hepatol 2021;33(1S Suppl 1):e66&#x2013;70.</Citation></Reference><Reference><Citation>de Moraes Andrade PV, Monteiro YM, Chehter EZ. Third-line and rescue therapy for refractory Helicobacter pylori infection: A systematic review. World J Gastroenterol 2023;29(2):390&#x2013;409.</Citation></Reference><Reference><Citation>Liou JM, Jiang XT, Chen CC, et al. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: A multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2023;8(3):228&#x2013;41.</Citation></Reference><Reference><Citation>Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: Expert review. Gastroenterology 2021;160(5):1831&#x2013;41.</Citation></Reference><Reference><Citation>Chen PY, Wu MS, Chen CY, et al. Systematic review with meta-analysis: The efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;44(5):427&#x2013;37.</Citation></Reference><Reference><Citation>Minakari M, Davarpanah Jazi AH, Shavakhi A, et al. A randomized controlled trial: Efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter 2010;15(2):154&#x2013;9.</Citation></Reference><Reference><Citation>Kuo CH, Hsu PI, Kuo FC, et al. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: A randomized controlled trial. J Antimicrob Chemother 2013;68(1):222&#x2013;8.</Citation></Reference><Reference><Citation>Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003;8(4):310&#x2013;9.</Citation></Reference><Reference><Citation>Gao CP, Zhou Z, Wang JZ, et al. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. J Dig Dis 2016;17(12):811&#x2013;9.</Citation></Reference><Reference><Citation>Bi H, Chen X, Chen Y, et al. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: A multicenter, prospective, randomized, controlled trial. Chin Med J (Engl) 2022;135(14):1707&#x2013;15.</Citation></Reference><Reference><Citation>Graham DY, Liou JM. Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship. Clin Gastroenterol Hepatol 2022;20(5):973&#x2013;83.e1.</Citation></Reference><Reference><Citation>Li H, Shen Y, Song X, et al. Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing. Helicobacter 2022;27(2):e12873.</Citation></Reference><Reference><Citation>Graham DY, Moss SF. Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: When, how, why. Am J Gastroenterol 2022;117(4):524&#x2013;8.</Citation></Reference><Reference><Citation>Smith SM, O'Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014;20(29):9912&#x2013;21.</Citation></Reference><Reference><Citation>Gong RJ, Xu CX, Li H, et al. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: A meta-analysis. World J Clin Cases 2021;9(1):133&#x2013;47.</Citation></Reference><Reference><Citation>Fernandez-Caso B, Miqueleiz A, Alarcon T. Whole genome sequencing for studying Helicobacter pylori antimicrobial resistance. Antibiotics (Basel) 2023;12(7):1135.</Citation></Reference><Reference><Citation>Hulten KG, Genta RM, Kalfus IN, et al. Comparison of culture with antibiogram to next-generation sequencing using bacterial isolates and formalin-fixed, paraffin-embedded gastric biopsies. Gastroenterology 2021;161(5):1433&#x2013;42.e2.</Citation></Reference><Reference><Citation>Argueta EA, Alsamman MA, Moss SF, et al. Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population. Gastroenterology 2021;160(6):2181&#x2013;3.e1.</Citation></Reference><Reference><Citation>Moss SF, Dang LP, Chua D, et al. Comparable results of Helicobacter pylori antibiotic resistance testing of stools vs gastric biopsies using next-generation sequencing. Gastroenterology 2022;162(7):2095&#x2013;7.e2.</Citation></Reference><Reference><Citation>Nyssen OP, Espada M, Gisbert JP. Empirical vs. susceptibility-guided treatment of Helicobacter pylori infection: A systematic review and meta-analysis. Front Microbiol 2022;13:913436.</Citation></Reference><Reference><Citation>Ma Q, Li H, Liao J, et al. Tailored therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Front Pharmacol 2022;13:908202.</Citation></Reference><Reference><Citation>Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: A randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18(8):791&#x2013;7.</Citation></Reference><Reference><Citation>Liou JM, Chen PY, Luo JC, et al. Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection. Gastroenterology 2018;155(4):1109&#x2013;19.</Citation></Reference><Reference><Citation>Chen MJ, Chen PY, Fang YJ, et al. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: Two multicentre, open-label, randomised controlled, non-inferiority trials. Lancet Gastroenterol Hepatol 2023;8(7):623&#x2013;34.</Citation></Reference><Reference><Citation>Lu M, Yu S, Deng J, et al. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: A meta-analysis of randomized controlled trials. PLoS One 2016;11(10):e0163743.</Citation></Reference><Reference><Citation>Wang F, Feng J, Chen P, et al. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol 2017;41(4):466&#x2013;75.</Citation></Reference><Reference><Citation>Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore) 2019;98(15):e15180.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>